Clinical trials: Recurrent Small Cell Lung Carcinoma
Non-small Cell Lung Cancer
Special Drug Use-results Surveillance of Tabrecta Tablets
This study was an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance.
- Trial name
- NCT04575025
- Testing
- Tabrecta tablets
- Where
- 78 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of rebeccamycin analogue is more effective in treating non-small cell lung…
- Trial name
- NCT00006017
- Testing
- becatecarin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02819024
- Testing
- Dexamethasone, Device for PET, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897533
- Testing
- gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis
- Volunteers
- 137 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00052494
- Testing
- cisplatin, imatinib mesylate, irinotecan hydrochloride
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05096663
- Testing
- Cobalamin, Dexamethasone, Docetaxel
- Where
- 350 sites in United States
- Volunteers
- 82 people
- Sponsor
- SWOG Cancer Research Network
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back.
- Conditions
- KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02642042
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Trametinib
- Where
- 596 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer.
- Trial name
- NCT01026467
- Testing
- cisplatin, carboplatin, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anxiety Disorder, Depression
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue…
- Conditions
- Anxiety Disorder, Depression, Fatigue, Lung Cancer
- Trial name
- NCT00005850
- Testing
- cisplatin, fluoxetine, gemcitabine hydrochloride
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Lung Cancer Metastatic
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory lung…
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent
- Trial name
- BAH2472 (NCT06538012)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation.
- Conditions
- EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02949843
- Testing
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Carcinoma, Non-Small-Cell Lung
Long-term Observation PMS for Afatinib
In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data for reexamination.
- Trial name
- NCT02131259
- Testing
- Afatinib dimaleate
- Where
- 432 sites in Japan
- Volunteers
- 1,605 people
- Sponsor
- Boehringer Ingelheim
Lung Neoplasms, Second Primary Lung Cancer (SPLC)
Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations
This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population.
- Conditions
- Lung Neoplasms, Second Primary Lung Cancer (SPLC), Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA, Lung Cancer (Diagnosis)
- Trial name
- PLuS2 (NCT07581379)
- Where
- United States
- Volunteers
- 1,826 people
- Sponsor
- University of Florida